Summary & Overview
HCPCS Level II J8562: Fludarabine Phosphate Oral 10 mg
HCPCS Level II code J8562 designates fludarabine phosphate, oral, 10 mg. This code is used to bill for a specific oral cytotoxic agent formulation and matters nationally because oral oncology medications are increasingly dispensed through outpatient pharmacies and influence cost-sharing, prior authorization, and benefit design across commercial and public payers. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of clinical context for fludarabine phosphate as an oral antineoplastic, typical sites of service where billing occurs, and the payer coverage environment for this HCPCS Level II code. The publication outlines common billing and documentation considerations, coding relationships, and where to find policy or coverage guidance. It also highlights benchmarks and policy updates relevant to oral chemotherapy billing and logistics, including reimbursement patterns and payer policy trends when available. Data not available in the input is indicated where applicable, and the content focuses on national implications rather than state-level specifics.
Billing Code Overview
HCPCS Level II code J8562 represents fludarabine phosphate, oral, 10 mg. This billing code denotes a specific oral formulation and dosage strength of fludarabine phosphate, an antineoplastic agent used in oncology care.
-
Service type: Oral chemotherapy medication
-
Typical site of service: Outpatient pharmacy dispensing or outpatient infusion/oncology clinic when administered as an oral systemic therapy
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with relapsed chronic lymphocytic leukemia (CLL) is prescribed oral fludarabine phosphate for outpatient administration. The medication J8562 represents fludarabine phosphate, oral, 10 mg, billed as a HCPCS Level II drug code for pharmacy or infusion clinic dispensing. Typical workflow: oncology clinic documents diagnosis, treatment plan, dosing schedule and obtains consent. Pharmacy verifies dose, prepares unit-dose tablets or blister packs, and dispenses with appropriate counseling. The patient receives the medication at home with scheduled follow-up telephone or clinic assessment for response and toxicity monitoring (hematologic counts, neurologic exam, renal function). Nursing documents education, adherence, and any adverse events. Billing uses the J8562 HCPCS code for each 10 mg unit dispensed; applicable modifiers may be appended to reflect unusual circumstances (e.g., non-routine handling, bilateral procedures are not applicable for oral drug). Typical site of service is outpatient oncology clinic, specialty pharmacy, or the patient's home when dispensed for take-home therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work or complexity related to drug preparation, documentation, or patient counseling substantially increases resource use beyond typical dispensing. |